Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other pharmaceutical manufacturers in Australasia: Probiotec Limited (2019 sales of 79.09 million Australian Dollars [US$47.13 million] ), AFT Pharmaceuticals Ltd of NEW ZEALAND (85.13 million New Zealand Dollars [US$49.78 million] of which 59% was Australia), and Palla Pharma Ltd (54.84 million Australian Dollars [US$32.68 million] of which 85% was Norway).

Sales Analysis. During the year ended June of 2019, sales at Mayne Pharma Group Limited were A$526.22 million (US$313.60 million). This is a decrease of 0.8% versus 2018, when the company's sales were A$530.43 million. Contributing to the drop in overall sales was the 16.8% decline in Generic Products, from A$385.70 million to A$320.77 million. . However, these declines were partially offset by the increase in sales of Specialty Brands (up 104.9% to A$91.56 million) and Metrics Contract Services (Mcs) (up 14.5% to A$72.20 million) and Mayne Pharma International (Mpi) (up 10.4% to A$40.68 million) .